GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF This study has been completed.

b><i>with slides</i></b> / Val-HeFT, a large randomized trial, shows the addition of valsartan, an angiotensin receptor blocker, to prescribed therapy did not reduce mortality ...

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759?766. [Order article via Infotrieve]

New results from the Val-HeFT trial show that while the addition of the angiotensin blocker valsartan to usual therapy did not affect all-cause mortality, the combined endpoint of ...

Preventing Congestive Heart Failure JAY N. COHN, M.D., University of Minnesota Medical School, Minneapolis, Minnesota. The morbidity, mortality and health care costs associated ...

LETTER TO THE EDITOR Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression Wei Jiang, MD a, Vic Hasselblad, PhD a, Ranga R.

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335:1107-14. Journal Club on the Web.

Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction Results of the CHARM Low-Left Ventricular ...

... 8.0 cohort morbidity and mortality for congestive heart failure ..... 35 8.1 intro duct ion ...

Novartis Reaches Recruitment Milestone in CHF Morbidity and Mortality Trial With Diovan(R)